MX363680B - Compuestos moduladores del canal de sodio (nav1. 7) y sus usos para el tratamiento del dolor neuropatico, nociceptivo o inflamatorio. - Google Patents
Compuestos moduladores del canal de sodio (nav1. 7) y sus usos para el tratamiento del dolor neuropatico, nociceptivo o inflamatorio.Info
- Publication number
- MX363680B MX363680B MX2015011907A MX2015011907A MX363680B MX 363680 B MX363680 B MX 363680B MX 2015011907 A MX2015011907 A MX 2015011907A MX 2015011907 A MX2015011907 A MX 2015011907A MX 363680 B MX363680 B MX 363680B
- Authority
- MX
- Mexico
- Prior art keywords
- pain
- treatment
- sodium channel
- channel modulators
- compounds
- Prior art date
Links
- 108010052164 Sodium Channels Proteins 0.000 title abstract 2
- 102000018674 Sodium Channels Human genes 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/50—Nitrogen atoms bound to hetero atoms
- C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Dermatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361787618P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/025809 WO2014151472A1 (en) | 2013-03-15 | 2014-03-13 | Sodium channel modulators for the treatment of pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015011907A MX2015011907A (es) | 2016-05-16 |
| MX363680B true MX363680B (es) | 2019-03-29 |
Family
ID=51580969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015011907A MX363680B (es) | 2013-03-15 | 2014-03-13 | Compuestos moduladores del canal de sodio (nav1. 7) y sus usos para el tratamiento del dolor neuropatico, nociceptivo o inflamatorio. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10179781B2 (OSRAM) |
| EP (1) | EP2968234B1 (OSRAM) |
| JP (1) | JP6449845B2 (OSRAM) |
| KR (1) | KR20150131254A (OSRAM) |
| CN (1) | CN105188694B (OSRAM) |
| AU (1) | AU2014234105B2 (OSRAM) |
| BR (1) | BR112015022096A8 (OSRAM) |
| CA (1) | CA2900604A1 (OSRAM) |
| ES (1) | ES2687481T3 (OSRAM) |
| HK (1) | HK1219060A1 (OSRAM) |
| IL (1) | IL242564A0 (OSRAM) |
| MX (1) | MX363680B (OSRAM) |
| MY (1) | MY188139A (OSRAM) |
| PH (1) | PH12015501740A1 (OSRAM) |
| RU (1) | RU2669367C2 (OSRAM) |
| WO (1) | WO2014151472A1 (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2586213T3 (es) | 2011-10-31 | 2016-10-13 | Xenon Pharmaceuticals Inc. | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos |
| CN104093716B (zh) | 2011-10-31 | 2017-06-23 | 克赛农制药股份有限公司 | 联芳醚磺酰胺化合物及其作为治疗剂的用途 |
| HK1209100A1 (en) | 2012-05-22 | 2016-03-24 | 基因泰克有限公司 | N-substituted benzamides and their use in the treatment of pain |
| KR101663436B1 (ko) | 2012-07-06 | 2016-10-06 | 제넨테크, 인크. | N-치환된 벤즈아미드 및 이의 사용 방법 |
| KR20150131233A (ko) | 2013-03-14 | 2015-11-24 | 제넨테크, 인크. | 치환된 트리아졸로피리딘 및 이의 사용 방법 |
| MX363680B (es) | 2013-03-15 | 2019-03-29 | Chromocell Corp | Compuestos moduladores del canal de sodio (nav1. 7) y sus usos para el tratamiento del dolor neuropatico, nociceptivo o inflamatorio. |
| WO2014144545A2 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
| CN105611923B (zh) * | 2013-09-10 | 2019-08-23 | 卓莫赛尔公司 | 用于治疗疼痛和糖尿病的钠通道调节剂 |
| CN105793238B (zh) | 2013-11-27 | 2019-12-24 | 基因泰克公司 | 经取代的苯甲酰胺及其使用方法 |
| EP3166939B1 (en) | 2014-07-07 | 2019-06-05 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| JP2017527573A (ja) * | 2014-09-09 | 2017-09-21 | クロモセル コーポレーション | 糖尿病の治療用の選択的ＮａＶ１．７阻害剤 |
| CN104710379B (zh) * | 2015-03-09 | 2017-01-18 | 华南理工大学 | 一种bms‑191011的合成方法 |
| US10179767B2 (en) | 2015-05-22 | 2019-01-15 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| EP3341353A1 (en) | 2015-08-27 | 2018-07-04 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| EP3356360A1 (en) | 2015-09-28 | 2018-08-08 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| EP3359151A4 (en) | 2015-10-07 | 2019-08-14 | Arizona Board of Regents on behalf of the University of Arizona | CRMP2 SUMOYLATION INHIBITORS AND USES THEREOF |
| MA43304A (fr) | 2015-11-25 | 2018-10-03 | Genentech Inc | Benzamides substitués utiles en tant que bloqueurs de canaux sodiques |
| TN2018000195A1 (en) | 2015-12-18 | 2019-10-04 | Merck Sharp & Dohme | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| EP3436432B1 (en) | 2016-03-30 | 2021-01-27 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| BR112019007763A2 (pt) | 2016-10-17 | 2019-07-02 | Genentech Inc | composto de fórmula, composição farmacêutica, métodos para tratar uma doença ou condição, para tratar dores, para diminuir o fluxo de íons e para tratar prurido, uso de um composto e invenção |
| CN110546148A (zh) | 2017-03-24 | 2019-12-06 | 基因泰克公司 | 作为钠通道抑制剂的4-哌啶-n-(嘧啶-4-基)色满-7-磺酰胺衍生物 |
| AR114263A1 (es) | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| CN111936494A (zh) | 2018-03-30 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪 |
| WO2019200369A1 (en) * | 2018-04-13 | 2019-10-17 | Chromocell Corporation | Compounds and methods of using compounds for the prevention or treatment of peripheral nerve damage |
| WO2019217822A1 (en) * | 2018-05-11 | 2019-11-14 | Chromocell Corporation | Compounds and methods of using compounds for the prevention or treatment of inflammatory conditions |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
| KR102812440B1 (ko) | 2018-09-10 | 2025-05-26 | 가껭세이야꾸가부시기가이샤 | 신규한 헤테로방향족 아미드 유도체 및 이를 함유하는 약제 |
| US20220125784A1 (en) * | 2019-02-04 | 2022-04-28 | Simon Fraser University | Methods and compounds for inhibition of inactivation of voltage-gated sodium channels |
| CN112759559B (zh) * | 2019-11-06 | 2022-08-12 | 成都康弘药业集团股份有限公司 | 作为钠通道阻滞剂的磺酰胺类化合物及其用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3905971A (en) * | 1971-03-29 | 1975-09-16 | Pfizer | 2-Phenyl-as-triazine-3,5(2H,4H)diones |
| US5356897A (en) | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| ATE404568T1 (de) * | 2001-03-14 | 2008-08-15 | Gruenenthal Gmbh | Substituierte thiazolopyrimidine als analgetika |
| US7659082B2 (en) | 2002-02-19 | 2010-02-09 | Xenon Pharmaceuticals Inc. | Methods for identifying analgesic agents |
| PL215132B1 (pl) | 2002-06-27 | 2013-10-31 | Novo Nordisk As | Pochodna arylokarbonylowa jako srodek terapeutyczny, jej zastosowanie i kompozycja farmaceutyczna ja zawierajaca |
| RU2006107211A (ru) * | 2003-08-08 | 2007-09-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Композиции, полезные в качестве ингибиторов потенциалозависимых натриевых каналов |
| GB0324792D0 (en) | 2003-10-23 | 2003-11-26 | Sterix Ltd | Compound |
| EP1689719A1 (en) | 2003-11-25 | 2006-08-16 | Eli Lilly And Company | 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b) |
| AU2005245386B2 (en) | 2004-05-07 | 2008-11-27 | Amgen Inc. | Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer |
| EA200700099A1 (ru) | 2004-07-23 | 2007-08-31 | Пфайзер Инк. | Производные пиридина |
| RS20070076A (sr) | 2004-10-29 | 2008-09-29 | Astrazeneca Ab., | Novi derivati sulfonamida kao modulatori glukokortikoidnog receptora za lečenje zapaljenskih bolesti |
| AR054394A1 (es) * | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de 2- (1h-indolilsulfanil)-aril amina |
| PT1966130E (pt) | 2005-12-23 | 2014-01-30 | Zealand Pharma As | Compostos miméticos de lisina modificados |
| EP2173743A2 (en) | 2007-07-13 | 2010-04-14 | Icagen, Inc. | Sodium channel inhibitors |
| JP5463285B2 (ja) | 2007-07-13 | 2014-04-09 | アイカジェン， インコーポレイテッド | ナトリウムチャネル阻害物質 |
| PL2385938T3 (pl) | 2009-01-12 | 2015-07-31 | Pfizer Ltd | Pochodne sulfonamidu |
| CN102448937A (zh) | 2009-05-29 | 2012-05-09 | 拉夸里亚创药株式会社 | 作为钙或钠通道阻滞剂的芳基取代羧酰胺衍生物 |
| JP2013525368A (ja) | 2010-04-23 | 2013-06-20 | キネタ・インコーポレイテツド | 抗ウイルス性化合物 |
| CA2804173C (en) | 2010-07-09 | 2015-01-13 | Pfizer Limited | Sulfonamide nav1.7 inhibitors |
| JP5860045B2 (ja) | 2010-07-09 | 2016-02-16 | ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ | 化合物 |
| CA2804593C (en) | 2010-07-09 | 2015-11-24 | Pfizer Limited | Biphenyloxybenzensulphonamide derivatives useful as sodium channel inhibitors |
| ES2532357T3 (es) | 2010-07-12 | 2015-03-26 | Pfizer Limited | Derivados de sulfonamida como inhibidores de Nav1.7 para el tratamiento del dolor |
| WO2012099983A1 (en) | 2011-01-18 | 2012-07-26 | Amgen Inc. | Nav1.7 knockout mice and uses thereof |
| AU2012296529A1 (en) | 2011-08-17 | 2014-02-20 | Amgen Inc. | Heteroaryl sodium channel inhibitors |
| EP2758053A1 (en) | 2011-09-21 | 2014-07-30 | Gilead Sciences, Inc. | Sodium channel blockers reduce glucagon secretion |
| CN104093716B (zh) | 2011-10-31 | 2017-06-23 | 克赛农制药股份有限公司 | 联芳醚磺酰胺化合物及其作为治疗剂的用途 |
| WO2014078479A2 (en) | 2012-11-14 | 2014-05-22 | The Board Of Regents Of The University Of Texas System | INHIBITION OF HIF-2α HETERODIMERIZATION WITH HIF1β (ARNT) |
| MX363680B (es) | 2013-03-15 | 2019-03-29 | Chromocell Corp | Compuestos moduladores del canal de sodio (nav1. 7) y sus usos para el tratamiento del dolor neuropatico, nociceptivo o inflamatorio. |
| PT3043784T (pt) | 2013-09-09 | 2019-08-02 | Peloton Therapeutics Inc | Aril éteres e utilizações dos mesmos |
| CN105611923B (zh) | 2013-09-10 | 2019-08-23 | 卓莫赛尔公司 | 用于治疗疼痛和糖尿病的钠通道调节剂 |
-
2014
- 2014-03-13 MX MX2015011907A patent/MX363680B/es unknown
- 2014-03-13 EP EP14767550.8A patent/EP2968234B1/en not_active Not-in-force
- 2014-03-13 RU RU2015133310A patent/RU2669367C2/ru not_active IP Right Cessation
- 2014-03-13 KR KR1020157029193A patent/KR20150131254A/ko not_active Abandoned
- 2014-03-13 CA CA2900604A patent/CA2900604A1/en active Pending
- 2014-03-13 HK HK16107214.7A patent/HK1219060A1/zh unknown
- 2014-03-13 US US14/776,016 patent/US10179781B2/en active Active
- 2014-03-13 JP JP2016501972A patent/JP6449845B2/ja active Active
- 2014-03-13 MY MYPI2015702635A patent/MY188139A/en unknown
- 2014-03-13 CN CN201480014410.XA patent/CN105188694B/zh not_active Expired - Fee Related
- 2014-03-13 ES ES14767550.8T patent/ES2687481T3/es active Active
- 2014-03-13 BR BR112015022096A patent/BR112015022096A8/pt not_active IP Right Cessation
- 2014-03-13 WO PCT/US2014/025809 patent/WO2014151472A1/en not_active Ceased
- 2014-03-13 AU AU2014234105A patent/AU2014234105B2/en not_active Ceased
-
2015
- 2015-08-07 PH PH12015501740A patent/PH12015501740A1/en unknown
- 2015-11-12 IL IL242564A patent/IL242564A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014234105B2 (en) | 2019-01-03 |
| EP2968234A4 (en) | 2016-10-12 |
| RU2015133310A3 (OSRAM) | 2018-02-28 |
| RU2669367C2 (ru) | 2018-10-11 |
| WO2014151472A1 (en) | 2014-09-25 |
| MY188139A (en) | 2021-11-23 |
| AU2014234105A1 (en) | 2015-09-03 |
| BR112015022096A2 (pt) | 2017-07-18 |
| HK1219060A1 (zh) | 2017-03-24 |
| EP2968234A1 (en) | 2016-01-20 |
| JP2016512844A (ja) | 2016-05-09 |
| CN105188694A (zh) | 2015-12-23 |
| JP6449845B2 (ja) | 2019-01-09 |
| BR112015022096A8 (pt) | 2019-11-26 |
| CN105188694B (zh) | 2018-07-31 |
| US20160046617A1 (en) | 2016-02-18 |
| US10179781B2 (en) | 2019-01-15 |
| CA2900604A1 (en) | 2014-09-25 |
| EP2968234B1 (en) | 2018-06-27 |
| KR20150131254A (ko) | 2015-11-24 |
| IL242564A0 (en) | 2016-02-29 |
| MX2015011907A (es) | 2016-05-16 |
| RU2015133310A (ru) | 2017-04-20 |
| ES2687481T3 (es) | 2018-10-25 |
| PH12015501740A1 (en) | 2015-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501740A1 (en) | Sodium channel modulators for the treatment of pain | |
| PH12016500296A1 (en) | Sodium channel modulators for the treatment of pain and diabetes | |
| PH12020500066A1 (en) | Carboxamides as modulators of sodium channels | |
| PH12016500105A1 (en) | Sulfonamides as modulators of sodium channels | |
| GEP20207082B (en) | Prodrugs of pyridone amides useful as modulators of sodium channels | |
| AU2018243463A8 (en) | 11,13-modified saxitoxins for the treatment of pain | |
| NZ710111A (en) | Quinoline and quinoxaline amides as modulators of sodium channels | |
| PH12015502161A1 (en) | Therapeutic compounds and compositions | |
| PH12015501661A1 (en) | Pyridone amides as modulators of sodium channels | |
| MX365525B (es) | Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia. | |
| NZ707778A (en) | Therapeutic compounds and compositions and their use as pkm2 modulators | |
| PH12015501609A1 (en) | Phenicol antibacterials | |
| MX392150B (es) | Moduladores de receptores canabinoides. | |
| MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
| TW201613578A (en) | Pharmaceutical combinations | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| MX2016006544A (es) | Witanolidos utiles para el tratamiento de enfermedades neurodegenerativas. | |
| MX368641B (es) | Compuestos para el tratamiento de inflamación y dolor. | |
| CY1118255T1 (el) | Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3 | |
| MX2016001357A (es) | Compuestos de ciclobutilo 1,2-disustituidos. | |
| EA202090268A1 (ru) | Карбоксамиды в качестве модуляторов натриевых каналов |